Family of genetic conditions caused by mutations affecting Ras genes
The RASopathies are a group of developmental syndromes caused by germline mutations in genes belonging to the Ras/MAPK pathway . Common features include intellectual disability , congenital heart defects , skin abnormalities, and craniofacial abnormalities .[ 1]
List of RASopathies
Known RASopathies include the following:[ 1] [ 2]
Somatic mutations in the Ras/MAPK pathway can cause cancers and disorders such as RAS-associated autoimmune leukoproliferative disorder (RALD) or juvenile myelomonocytic leukemia (JMML). These syndromes may share some features with RASopathies but are not considered true RASopathies if caused by somatic mutation.[ 3] Generally, RASopathies increase the risk of developing cancers.[ 1] [ 4] Neurodevelopmental or psychiatric disorders such as attention deficit hyperactivity disorder , autism spectrum disorder, and anxiety occur at higher rates in individuals with RASopathies.[ 5] [ 6]
Genetics
RASopathies are caused by germline mutations which result in overall activation of the Ras/MAPK pathway. Mutations in the following genes are associated with one or more types of RASopathy:[ 2] [ 7]
References
^ a b c Rauen KA (2022). "Defining RASopathy" . Disease Models & Mechanisms . 15 (2). doi :10.1242/dmm.049344 . PMC 8821523 . PMID 35103797 .
^ a b Tidyman WE, Rauen KA (2016). "Pathogenetics of the RASopathies" . Human Molecular Genetics . 25 (R2): R123 – R132 . doi :10.1093/hmg/ddw191 . PMC 6283265 . PMID 27412009 .
^ Riller Q, Rieux-Laucat F (2021). "RASopathies: From germline mutations to somatic and multigenic diseases" . Biomedical Journal . 44 (4): 422– 432. doi :10.1016/j.bj.2021.06.004 . PMC 8514848 . PMID 34175492 .
^ Dunnett-Kane V, Burkitt-Wright E, Blackhall FH, Malliri A, Evans DG, Lindsay CR (2020). "Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts" . Annals of Oncology . 31 (7): 873– 883. doi :10.1016/j.annonc.2020.03.291 . PMC 7322396 . PMID 32240795 . {{cite journal }}
: CS1 maint: multiple names: authors list (link )
^ Rai B, Naylor PE, Siqueiros-Sanchez M, Wintermark M, Raman MM, Jo B; et al. (2023). "Novel effects of Ras-MAPK pathogenic variants on the developing human brain and their link to gene expression and inhibition abilities" . Translational Psychiatry . 13 (1): 245. doi :10.1038/s41398-023-02504-4 . PMC 10322993 . PMID 37407569 . {{cite journal }}
: CS1 maint: multiple names: authors list (link )
^ Zenker M (2022). "Clinical overview on RASopathies" . American Journal of Medical Genetics Part C: Seminars in Medical Genetics . 190 (4): 414– 424. doi :10.1002/ajmg.c.32015 . PMID 36428239 .
^ Aoki Y, Niihori T, Inoue S, Matsubara Y (2016). "Recent advances in RASopathies". Journal of Human Genetics . 61 (1): 33– 9. doi :10.1038/jhg.2015.114 . PMID 26446362 . {{cite journal }}
: CS1 maint: multiple names: authors list (link )